5.76
price down icon2.54%   -0.15
after-market After Hours: 5.74 -0.02 -0.35%
loading
Iovance Biotherapeutics Inc stock is traded at $5.76, with a volume of 9.03M. It is down -2.54% in the last 24 hours and down -26.53% over the past month. Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
See More
Previous Close:
$5.91
Open:
$5.93
24h Volume:
9.03M
Relative Volume:
1.28
Market Cap:
$1.75B
Revenue:
$32.77M
Net Income/Loss:
$-440.22M
P/E Ratio:
-3.4491
EPS:
-1.67
Net Cash Flow:
$-400.48M
1W Performance:
-19.67%
1M Performance:
-26.53%
6M Performance:
-38.79%
1Y Performance:
-31.18%
1-Day Range:
Value
$5.62
$5.99
1-Week Range:
Value
$5.62
$7.025
52-Week Range:
Value
$5.62
$18.33

Iovance Biotherapeutics Inc Stock (IOVA) Company Profile

Name
Name
Iovance Biotherapeutics Inc
Name
Phone
(650) 260-7120
Name
Address
825 INDUSTRIAL ROAD, SAN CARLOS
Name
Employee
557
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
IOVA's Discussions on Twitter

Compare IOVA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
IOVA
Iovance Biotherapeutics Inc
5.76 1.75B 32.77M -440.22M -400.48M -1.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
416.96 107.75B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
693.23 76.83B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
659.81 39.72B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
249.16 32.48B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
112.76 27.01B 3.30B -501.07M 1.03B -2.1146

Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-24-24 Initiated UBS Buy
Jul-29-24 Downgrade Piper Sandler Overweight → Neutral
Nov-20-23 Initiated Goldman Buy
Sep-18-23 Reiterated Barclays Overweight
May-30-23 Upgrade Wells Fargo Equal Weight → Overweight
Mar-27-23 Resumed Wells Fargo Equal Weight
Jan-27-23 Upgrade Piper Sandler Neutral → Overweight
Dec-09-22 Downgrade Goldman Buy → Neutral
Oct-31-22 Initiated Guggenheim Neutral
Aug-18-22 Resumed Wells Fargo Equal Weight
Jan-28-22 Upgrade Stifel Hold → Buy
Dec-07-21 Resumed Cowen Outperform
Jun-10-21 Upgrade JMP Securities Mkt Perform → Mkt Outperform
May-20-21 Downgrade Piper Sandler Overweight → Neutral
May-19-21 Downgrade JMP Securities Mkt Outperform → Mkt Perform
May-19-21 Downgrade Stifel Buy → Hold
May-03-21 Initiated Truist Buy
Apr-16-21 Initiated Goldman Buy
Mar-08-21 Upgrade H.C. Wainwright Neutral → Buy
Dec-15-20 Downgrade H.C. Wainwright Buy → Neutral
Oct-06-20 Downgrade Wells Fargo Overweight → Equal Weight
Apr-22-20 Initiated Mizuho Buy
Mar-04-20 Initiated Barclays Overweight
Feb-26-20 Reiterated H.C. Wainwright Buy
Feb-26-20 Reiterated Oppenheimer Outperform
Dec-18-19 Initiated JMP Securities Mkt Outperform
Oct-01-19 Initiated Stifel Buy
Apr-29-19 Initiated Piper Jaffray Overweight
Feb-28-19 Reiterated Chardan Capital Markets Buy
Feb-07-19 Initiated Robert W. Baird Outperform
Dec-31-18 Resumed B. Riley FBR Buy
Jul-06-18 Reiterated Chardan Capital Markets Buy
Apr-10-18 Upgrade B. Riley FBR, Inc. Neutral → Buy
Mar-13-18 Reiterated B. Riley FBR, Inc. Neutral
Feb-23-18 Downgrade B. Riley FBR, Inc. Buy → Neutral
Jan-25-18 Reiterated H.C. Wainwright Buy
Nov-01-17 Reiterated B. Riley FBR, Inc. Buy
View All

Iovance Biotherapeutics Inc Stock (IOVA) Latest News

pulisher
07:04 AM

Iovance Biotherapeutics (NASDAQ:IOVA) Sets New 52-Week LowShould You Sell? - MarketBeat

07:04 AM
pulisher
Jan 13, 2025

Oversold Conditions For Iovance Biotherapeutics (IOVA) - Nasdaq

Jan 13, 2025
pulisher
Jan 11, 2025

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) May Have Run Too Fast Too Soon With Recent 25% Price Plummet - Simply Wall St

Jan 11, 2025
pulisher
Jan 11, 2025

How To Trade (IOVA) - Stock Traders Daily

Jan 11, 2025
pulisher
Jan 10, 2025

Cancer Drug Maker Iovance Tumbles Toward Worst Week Since November, But Retail Feels Macro Selloff Overblown - MSN

Jan 10, 2025
pulisher
Jan 10, 2025

Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 7.8%Here's Why - MarketBeat

Jan 10, 2025
pulisher
Jan 10, 2025

Iovance Biotherapeutics Shares Are Falling Today: What's Going On? - Benzinga

Jan 10, 2025
pulisher
Jan 09, 2025

Immunotoxins Market Trends and Regional Business Opportunities, 2024-2034: Diphtheria Toxin-Based Immunotoxins Lead Revenue, Pseudomonas Exotoxins Show Rapid Growth Potential - GlobeNewswire Inc.

Jan 09, 2025
pulisher
Jan 03, 2025

Why Iovance Biotherapeutics Stock Zoomed More Than 5% Higher Today - MSN

Jan 03, 2025
pulisher
Jan 02, 2025

Iovance Biotherapeutics (IOVA) Surges on Positive Analyst Outlook - GuruFocus.com

Jan 02, 2025
pulisher
Jan 02, 2025

Stifel maintains Buy on Iovance Biotherapeutics stock, optimistic on Amtagvi By Investing.com - Investing.com Canada

Jan 02, 2025
pulisher
Jan 02, 2025

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 7.7%What's Next? - MarketBeat

Jan 02, 2025
pulisher
Jan 02, 2025

Why Iovance Biotherapeutics Inc. (IOVA) Is Skyrocketing - MSN

Jan 02, 2025
pulisher
Jan 02, 2025

Analysts Set Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Price Target at $23.00 - MarketBeat

Jan 02, 2025
pulisher
Dec 31, 2024

Philly’s year in biopharma: a look back at 2024 - The Philadelphia Inquirer

Dec 31, 2024
pulisher
Dec 26, 2024

The Immunotherapy Boom: What It Means for the Future of Cancer Treatment - Baystreet.ca

Dec 26, 2024
pulisher
Dec 24, 2024

Principal Financial Group Inc. Has $37.87 Million Stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

Dec 24, 2024
pulisher
Dec 23, 2024

Geode Capital Management LLC Cuts Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

Dec 23, 2024
pulisher
Dec 21, 2024

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Purchased by Barclays PLC - MarketBeat

Dec 21, 2024
pulisher
Dec 21, 2024

Where are the Opportunities in (IOVA) - Stock Traders Daily

Dec 21, 2024
pulisher
Dec 20, 2024

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times

Dec 20, 2024
pulisher
Dec 19, 2024

Insiders' US$48.3m Investments In Red Following Iovance Biotherapeutics' US$402m Dip In Market Value - Simply Wall St

Dec 19, 2024
pulisher
Dec 18, 2024

Iovance Biotherapeutics is Now Oversold (IOVA) - Nasdaq

Dec 18, 2024
pulisher
Dec 17, 2024

KEI Comments on NIH Exclusive License to Iovance for T-cell Vaccine for Cancer Treatment - Knowledge Ecology International

Dec 17, 2024
pulisher
Dec 16, 2024

Iovance Biotherapeutics: Amtagvi Launch Growing, But Stock Isn't (NASDAQ:IOVA) - Seeking Alpha

Dec 16, 2024
pulisher
Dec 16, 2024

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Sees Significant Increase in Short Interest - MarketBeat

Dec 16, 2024
pulisher
Dec 15, 2024

State Street Corp Grows Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

Dec 15, 2024
pulisher
Dec 13, 2024

Iovance Biotherapeutics' SWOT analysis: promising TIL therapy stock faces growth hurdles - Investing.com India

Dec 13, 2024
pulisher
Dec 12, 2024

Interesting IOVA Call Options For January 2025 - Nasdaq

Dec 12, 2024
pulisher
Dec 12, 2024

Prediction: This Stock Will Beat the Market in 2025 - Yahoo Finance

Dec 12, 2024
pulisher
Dec 11, 2024

BNP Paribas Financial Markets Trims Stock Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

Dec 11, 2024
pulisher
Dec 09, 2024

Iovance Biotherapeutics' SWOT analysis: stock shows promise amid challenges By Investing.com - Investing.com Nigeria

Dec 09, 2024
pulisher
Dec 09, 2024

Iovance Biotherapeutics: Steady Progress (NASDAQ:IOVA) - Seeking Alpha

Dec 09, 2024
pulisher
Dec 08, 2024

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Dec 08, 2024
pulisher
Dec 07, 2024

Charles Schwab Investment Management Inc. Has $17.96 Million Stock Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

Dec 07, 2024
pulisher
Dec 06, 2024

Iovance's (IOVA) Q4 Earnings & Sales Fall Short of Estimates - MSN

Dec 06, 2024
pulisher
Dec 03, 2024

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a favorite amongst institutional investors who own 63% - Yahoo Finance

Dec 03, 2024
pulisher
Nov 30, 2024

Braidwell LP Has $2.05 Million Stock Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

Nov 30, 2024
pulisher
Nov 29, 2024

(IOVA) On The My Stocks Page - Stock Traders Daily

Nov 29, 2024
pulisher
Nov 29, 2024

Iovance (IOVA) Gears Up for Q1 Earnings: Here's What to Expect - MSN

Nov 29, 2024
pulisher
Nov 29, 2024

Intech Investment Management LLC Makes New $920,000 Investment in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

Nov 29, 2024
pulisher
Nov 28, 2024

IOVAIovance Biotherapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Nov 28, 2024
pulisher
Nov 27, 2024

Is Iovance Biotherapeutics Stock a Millionaire Maker? - MSN

Nov 27, 2024

Iovance Biotherapeutics Inc Stock (IOVA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Iovance Biotherapeutics Inc Stock (IOVA) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Vogt Frederick G
Interim CEO & General Counsel
Dec 02 '24
Option Exercise
0.00
10,417
0
214,662
BILINSKY IGOR
Chief Operating Officer
Dec 02 '24
Option Exercise
0.00
3,516
0
59,323
GRAF FINCKENSTEIN FRIEDRICH
Chief Medical Officer
Dec 02 '24
Option Exercise
0.00
3,906
0
64,633
Maynard Ryan D
Director
Nov 12 '24
Option Exercise
7.45
50,000
372,500
57,500
Maynard Ryan D
Director
Nov 12 '24
Sale
10.06
50,000
503,000
7,500
$18.19
price down icon 0.05%
$30.95
price up icon 0.68%
$72.47
price up icon 0.01%
$366.39
price up icon 1.31%
biotechnology ONC
$205.34
price up icon 1.79%
$112.76
price down icon 0.80%
Cap:     |  Volume (24h):